We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Novavax. This level of activity is out of the ordinary.
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.
On Thursday, Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $9.18 which represents a slight increase of $0.22 or 2.46% from the prior close of $8.96. The stock opened at $9.16 and ...
Novavax, Inc. (NASDAQ:NVAX – Get Free Report) has been assigned an average rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat.com reports. One research ...
Some results have been hidden because they may be inaccessible to you